# SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

> **NCT00365274** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **DRUG:** SGN-30

## Key facts

- **NCT ID:** NCT00365274
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365274, "SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00365274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*